🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating around the world, with estimates suggesting in excess of 82 million infections each year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Global Access

Based on results published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This puts it on an comparable level with the typical regimen, which combines an injection and a pill. The trial enrolled nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals on the front lines have voiced hope. The availability of a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is deemed essential to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.